Michael Czapka, MD, is an infectious disease doctor who specializes in treating and preventing infections in immunocompromised adults. Dr. Czapka provides care for people before and after organ transplants, chemotherapy, stem cell transplants and CAR T-cell therapy, with particular expertise managing fungal and viral infections.
Along with his dedication to his patients, Dr. Czapka is actively involved in clinical trials for new drugs and vaccines targeted to difficult-to-treat infections, including fungi and viruses. He also studies infections in CAR T-cell recipients and leads quality improvement initiatives at the hospital. Additionally, Dr. Czapka serves on the institutional ethics review board for clinical research and assists with board exam development within his specialty.
Interventions to Improve Life Participation in Kidney Transplant Recipients: A Systematic Review.
Interventions to Improve Life Participation in Kidney Transplant Recipients: A Systematic Review. Kidney Med. 2025 Apr; 7(4):100980.
PMID: 40212318
In Reply to "ACGME Accreditation for Transplant Nephrology Training: Clarifying Why This Is a Step in the Right Direction".
In Reply to "ACGME Accreditation for Transplant Nephrology Training: Clarifying Why This Is a Step in the Right Direction". Am J Kidney Dis. 2025 Apr; 85(4):527-528.
PMID: 39580067
ACGME Accreditation for Transplant Nephrology Training: Clarifying Why This Is a Step in the Right Direction.
ACGME Accreditation for Transplant Nephrology Training: Clarifying Why This Is a Step in the Right Direction. Am J Kidney Dis. 2025 Apr; 85(4):527.
PMID: 39571927
Prostate cancer and solid organ transplantation: patient management and outcomes.
Prostate cancer and solid organ transplantation: patient management and outcomes. BJU Int. 2025 Feb; 135(2):339-345.
PMID: 39385314
Evaluation of a Ureteral Stent Removal Protocol in Adult Kidney Transplant Recipients.
Evaluation of a Ureteral Stent Removal Protocol in Adult Kidney Transplant Recipients. Open Forum Infect Dis. 2024 Sep; 11(9):ofae510.
PMID: 39310271
A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy.
A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy. Transpl Infect Dis. 2024 Dec; 26(6):e14367.
PMID: 39226143
Working Together to Promote Kidney Health.
Working Together to Promote Kidney Health. Nephrol Nurs J. 2024 Jul-Aug; 51(4):333-368.
PMID: 39230463
The Seattle Heart Failure Model in Kidney Transplant Recipients.
The Seattle Heart Failure Model in Kidney Transplant Recipients. J Clin Med. 2023 Dec 11; 12(24).
PMID: 38137683
The authors reply.
The authors reply. Kidney Int. 2023 12; 104(6):1227.
PMID: 37981433
Validation of a Core Patient-Reported Outcome Measure for Life Participation in Kidney Transplant Recipients: the SONG Life Participation Instrument.
Validation of a Core Patient-Reported Outcome Measure for Life Participation in Kidney Transplant Recipients: the SONG Life Participation Instrument. Kidney Int Rep. 2024 Jan; 9(1):87-95.
PMID: 38312789